Operating Segments

9 Months Ended

Sep. 30, 2014

Operating Segments [Abstract]

Operating Segments

Note 8. Operating Segments

The Company maintains two active operating segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	Three Months Ended September 30,
	2014			2013
Contract/Grant Revenue
Vaccines/BioDefense	$	2,729,854		$	264,920
BioTherapeutics		57,855			47,571
Total	$	2,787,709		$	312,491
Income (Loss) from Operations
Vaccines/BioDefense	$	545,728		$	(419,929	)
BioTherapeutics		(4,855,765	)		(1,080,436	)
Corporate		(831,341	)		(360,297	)
Total	$	(5,141,378	)	$	(1,860,662	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	9,922		$	28,316
BioTherapeutics		49,985			29,233
Corporate		1,561			551
Total	$	61,468		$	58,100
Other Income /(Expense), Net
Corporate	$	791,823		$	(4,699,194	)
Stock-Based Compensation
Vaccines/BioDefense	$	17,224		$	39,493
BioTherapeutics		33,118			158,142
Corporate		110,653			209,256
Total	$	160,995		$	406,891

	Nine Months Ended  September 30,
	2014			2013
Revenues, Principally from Grants
Vaccines/BioDefense	$	4,928,284		$	1,683,265
BioTherapeutics		188,270			161,858
Total	$	5,116,554		$	1,845,123
Income (Loss) from Operations
Vaccines/BioDefense	$	949,032		$	(1,983,396	)
BioTherapeutics		(6,541,832	)		(2,068,703	)
Corporate		(2,834,318	)		(1,652,344	)
Total	$	(8,427,118	)	$	(5,704,443	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	29,666		$	83,951
BioTherapeutics		148,995			86,303
Corporate		5,299			1,412
Total	$	183,960		$	171,666
Other Income /(Expense), Net
Corporate	$	(202,662	)	$	(5,347,984	)
Stock-Based Compensation
Vaccines/BioDefense	$	38,124		$	61,742
BioTherapeutics		142,374			205,083
Corporate		278,416			304,346
Total	$	458,914		$	571,171

	As of  September 30,  2014		As of  December 31,  2013
Identifiable Assets
Vaccines/BioDefense	$	1,566,050	$	1,870,414
BioTherapeutics		265,939		386,721
Corporate		4,440,953		6,008,320
Total	$	6,272,942	$	8,265,455